Drug intelligence / Profile preview

NB-1002

Development stage: Discontinued
Lead developer: Innovate Biopharmaceuticals
Modality: Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

**NB-1002** is a glucagon-like peptide-2 (GLP-2) receptor agonist developed as an XTEN fusion protein, a recombinant polypeptide engineered by fusing GLP-2 with XTEN technology to extend half-life and improve pharmacokinetics for chronic administration. Initially developed by Amunix, Inc. and licensed to Naia Rare Diseases, it was designed primarily for short bowel syndrome, an orphan gastrointestinal indication, by promoting intestinal adaptation and nutrient absorption. Its development has been discontinued globally.

Other names: GLP-2-XTENGLP2-XTENGLP 2-XTEN

Targets

GLP2R (Glucagon-like peptide 2 receptor)

Beyond the preview

Go deeper on NB-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB-1002.

Explore the full profile